Strongbridge Biopharma Stock Price, News & Analysis (NASDAQ:SBBP)

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its quarterly earnings results on Wednesday, July, 31st. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.01. The biotechnology company had revenue of $6.08 million for the quarter, compared to analysts' expectations of $4.82 million. Strongbridge Biopharma had a return on equity of 49.92% and a net margin of 181.52%. View Strongbridge Biopharma's Earnings History.

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Strongbridge Biopharma.

Strongbridge Biopharma issued an update on its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $18-20 million, compared to the consensus revenue estimate of $19.49 million.

6 Wall Street analysts have issued 1 year price targets for Strongbridge Biopharma's stock. Their forecasts range from $8.00 to $15.00. On average, they expect Strongbridge Biopharma's stock price to reach $11.50 in the next year. This suggests a possible upside of 477.9% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

News articles about SBBP stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Strongbridge Biopharma earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Strongbridge Biopharma.

Strongbridge Biopharma saw a increase in short interest in September. As of September 30th, there was short interest totalling 701,500 shares, an increase of 5.6% from the August 30th total of 664,200 shares. Based on an average daily volume of 164,300 shares, the short-interest ratio is currently 4.3 days. Approximately 2.1% of the company's stock are sold short. View Strongbridge Biopharma's Current Options Chain.

Some companies that are related to Strongbridge Biopharma include Progenics Pharmaceuticals (PGNX), Evolus (EOLS), Avedro (AVDR), Crinetics Pharmaceuticals (CRNX), Collegium Pharmaceutical (COLL), Assembly Biosciences (ASMB), Synthorx (THOR), Stemline Therapeutics (STML), Beyondspring (BYSI), AMAG Pharmaceuticals (AMAG), Arcus Biosciences (RCUS), Verrica Pharmaceuticals (VRCA), Magenta Therapeutics (MGTA), DURECT (DRRX) and Merus (MRUS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include Energy Transfer LP Unit (ET), Dicerna Pharmaceuticals (DRNA), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), CBL & Associates Properties (CBL), Dynavax Technologies (DVAX), SunCoke Energy Partners (SXCP), Abeona Therapeutics (ABEO), Ocular Therapeutix (OCUL) and Progenics Pharmaceuticals (PGNX).

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBBP stock can currently be purchased for approximately $1.99.

Strongbridge Biopharma has a market capitalization of $107.84 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]